Literature DB >> 10552983

Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.

K E Bowker1, M Wootton, C A Rogers, R Lewis, H A Holt, A P MacGowan.   

Abstract

The pharmacodynamics of ciprofloxacin were explored in an in-vitro continuous bacterial culture model of infection, by simulating two oral dosing regimens; 0.5 g 12-hourly (bd) and 1 g 24-hourly (od). Three strains of Escherichia coli (ciprofloxacin MICs 0.03, 0.5 and 2 mg/L); two strains of Pseudomonas aeruginosa (MICs 0.09 and 1.5 mg/L), two strains of Staphylococcus aureus (MICs 0.12 and 1 mg/L) and two strains of Streptococcus pneumoniae (MICs 0.5 and 2 mg/L) were used. Three pharmacodynamic parameters, T > MIC, C(max)/MIC and AUC/MIC (T = time, C(max) = peak serum concentration, AUC = area under the curve), were compared with area under the bacterial-kill curve (AUBKC) (after transformation of the AUBKC) using a simple E(max) or sigmoidal E(max) model. AUBKC was taken to be the main antibacterial effect measure. The models were compared by inspection of residuals and Akaike information criterion. E(max) models adequately described the relationship between AUC/MIC and AUBKC and between C(max)/MIC and AUBKC, but not between T> MIC and AUBKC. All three pharmacodynamic parameters are related to each other but multiple regression analysis indicated that AUC/MIC was the best individual predictor of AUBKC. Despite this, comparison of od and bd regimens indicates some advantage to od in terms of early antibacterial effect. Serum concentration-time curve shape has some importance in determining antibacterial effect. These data indicate that for ciprofloxacin AUC/MIC ratio is not the sole determinant of antibacterial effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552983     DOI: 10.1093/jac/44.5.661

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones.

Authors:  Masaya Takei; Yuko Yamaguchi; Hideyuki Fukuda; Mitsuru Yasuda; Takashi Deguchi
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.

Authors:  A P MacGowan; C A Rogers; H A Holt; M Wootton; K E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.

Authors:  Boubakar B Ba; Corinne Arpin; Céline Vidaillac; Arnaud Chausse; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Modeling the growth dynamics of multiple Escherichia coli strains in the pig intestine following intramuscular ampicillin treatment.

Authors:  Amais Ahmad; Camilla Zachariasen; Lasse Engbo Christiansen; Kaare Græsbøll; Nils Toft; Louise Matthews; Søren Saxmose Nielsen; John Elmerdahl Olsen
Journal:  BMC Microbiol       Date:  2016-09-06       Impact factor: 3.605

7.  Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Boubakar B Ba; Hala Feghali; Corinne Arpin; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

8.  An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis.

Authors:  Niina Ahola; Noora Männistö; Minna Veiranto; Matti Karp; Jaana Rich; Alexander Efimov; Jukka Seppälä; Minna Kellomäki
Journal:  Biomatter       Date:  2013-01-01

9.  Pharmacodynamic modelling of in vitro activity of tetracycline against a representative, naturally occurring population of porcine Escherichia coli.

Authors:  Amais Ahmad; Camilla Zachariasen; Lasse Engbo Christiansen; Kaare Græsbøll; Nils Toft; Louise Matthews; Peter Damborg; Yvonne Agersø; John Elmerdahl Olsen; Søren Saxmose Nielsen
Journal:  Acta Vet Scand       Date:  2015-11-24       Impact factor: 1.695

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.